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Simple Summary: High-grade serous ovarian cancer (HGSOC) accounts for 70% of ovarian carci-
nomas with sobering survival rates. The mechanisms mediating treatment efficacy are still poorly
understood with no adequate biomarkers of response to treatment and risk assessment. This variabil-
ity of treatment response might be due to its molecular heterogeneity. Therefore, identification of
biomarkers or molecular signatures to stratify patients and offer personalized treatment is of utmost
priority. Currently, comprehensive gene expression profiling is time- and cost-extensive and limited
by tissue heterogeneity. Thus, it has not been implemented into clinical practice. This study demon-
strates for the first time a spatially resolved, time- and cost-effective approach to stratifying HGSOC
patients by combining novel matrix-assisted laser desorption/ionization imaging mass spectrometry
(MALDI-IMS) technology with machine-learning algorithms. Eventually, MALDI-derived predictive
signatures for treatment efficacy, recurrent risk, or, as demonstrated here, molecular subtypes might
be utilized for emerging clinical challenges to ultimately improve patient outcomes.
Abstract: Despite the correlation of clinical outcome and molecular subtypes of high-grade serous
ovarian cancer (HGSOC), contemporary gene expression signatures have not been implemented in
clinical practice to stratify patients for targeted therapy. Hence, we aimed to examine the potential of
unsupervised matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS)
to stratify patients who might benefit from targeted therapeutic strategies. Molecular subtyping of
paraffin-embedded tissue samples from 279 HGSOC patients was performed by NanoString analysis
(ground truth labeling). Next, we applied MALDI-IMS paired with machine-learning algorithms to
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identify distinct mass profiles on the same paraffin-embedded tissue sections and distinguish HGSOC
subtypes by proteomic signature. Finally, we devised a novel approach to annotate spectra of stromal
origin. We elucidated a MALDI-derived proteomic signature (135 peptides) able to classify HGSOC
subtypes. Random forest classifiers achieved an area under the curve (AUC) of 0.983. Furthermore,
we demonstrated that the exclusion of stroma-associated spectra provides tangible improvements
to classification quality (AUC = 0.988). Moreover, novel MALDI-based stroma annotation achieved
near-perfect classifications (AUC = 0.999). Here, we present a concept integrating MALDI-IMS with
machine-learning algorithms to classify patients according to distinct molecular subtypes of HGSOC.
This has great potential to assign patients for personalized treatment.
Keywords: ovarian cancer; molecular subtypes; diagnostic classifier; MALDI-IMS
1. Introduction
High-grade serous ovarian cancer (HGSOC) is the most common histological sub-
type of ovarian cancer to be diagnosed clinically. Due to a lack of adequate early-stage
detection, HGSOC accounts for a majority of ovarian cancer-related deaths [1]. Treatment
with platinum-based chemotherapy following primary debulking surgery will initially
lead to a complete response in most patients. However, more than 70% of patients will
eventually relapse, subsequently develop chemotherapy resistance, and die of the disease.
Unfortunately, patient survival has only slightly improved in past decades. Particularly, the
introduction of poly (ADP-ribose) polymerase (PARP) inhibitors has reduced the relapse
rates within the first 5 years after diagnosis to 50% [2]. Nevertheless, novel therapeutic
approaches are crucial to having a more profound impact on patient survival [3]. In this
context, diagnostic biomarkers are required to stratify patients for personalized treatment.
Several investigations have demonstrated that HGSOC is molecularly heterogeneous
and comprises four molecular subtypes based on microarray analysis—mesenchymal
(C1) with high stromal content, immunoreactive (C2) with high expression of T-cell mark-
ers, major histocompatibility complex genes, and programmed cell death and ligand 1
(PD1 and PDL1) levels, differentiated (C4) and proliferative (C5) with high expression
of transcription factors and proliferative markers, each with distinct gene expression sig-
natures and consequently, an impact on tumor biology, chemotherapy resistance, and
patient outcomes [4–8]. However, the regulatory mechanisms and key signaling kinases
of the oncogenic pathways driving these phenotypes are poorly understood and a better
comprehension of the complex signaling network in HGSOC cells might generate novel
therapeutic opportunities.
Gene expression data have been instrumental in dissecting the underlying biological
processes and pathways of tumor progression. Gene set enrichment analysis (GSEA) of
the molecular subtype signatures demonstrated that C1, characterized by extensive myofi-
broblast infiltration, was associated with processes like extracellular matrix remodeling
(ECM), angiogenesis, and high expression of genes in the transforming growth factor-β
(TGF-β) signaling pathway. Pathway enrichment analysis also revealed specific pathways
associated with molecular signatures of C2 (e.g., PD1/PD-L1 and T-cell receptor (TCR)
signaling), C4 (e.g., PDGF, FGF, and CREB signaling pathways) and C5 (e.g., define each
signaling) subtypes of HGSOC [6–9].
Furthermore, a detailed network-based strategy with implementing a master regulator
analysis (MRA) algorithm to the network indicated that mesenchymal master regulators
(MRs) increased upon metastasis and chemotherapy and correlated significantly with poor
prognosis. Moreover, this approach led to the identification of novel transcription factors,
which also served as prognostic biomarkers. Conversely, immunoreactive MRs showed
significant association with improved overall survival, which is in line with previous
findings for subtype-specific gene expression signatures [9,10].
Cancers 2021, 13, 1512 3 of 13
Even though novel therapeutic targets emerge, these subtypes and identified targets
are not yet introduced in the clinical routine, partly due to the time and cost of gene
expression profiling [11,12]. Tumor heterogeneity, a hallmark of HGSOC, is another issue,
which highlights the limitations of gene expression profiling on RNA samples from bulk
tumor tissue, such that the diversity within HGSOC is currently not well understood. It
has been shown that these subtypes are not exclusive and that 40% of cancers could be
assigned to two subtypes [13,14].
Moreover, these subtypes are strongly associated with cells in the microenvironment.
Yet, molecular analysis of tumors consisting of malignant cells and normal tissue types is
challenging [15]. This has been observed recently when published prognostic gene signatures
were no longer prognostic in multivariate models after adjustment for high stromal con-
tent [16]. Hence, to improve the reliability of subtype classification, stromal content should be
accounted for, especially if the tumor contains low numbers of malignant cells. Because of the
heterogeneous nature of the disease, a limitation of large-scale publicly available gene expres-
sion datasets is in general the validation of prognostic or subtype signatures. To circumvent
this problem, subtype classification should be performed in representative, corresponding
tumor tissue. Gene expression profiling using RNA from formalin-fixed paraffin-embedded
tissue (FFPE) allows for the validation of both spatial and temporal protein expression on the
same tumor sections by immunohistochemistry (IHC).
Leong et al. (2015) developed such an assay on FFPE tissue for molecular classification
based on previously generated microarray data for the efficient molecular classification of
HGSOC by quantifying a limited number of genes using NanoString technology (NanoS-
tring Technologies, Seattle, WA, USA) [17–19].
A promising unsupervised approach capable of measuring a wide spectrum of
molecules directly is MALDI-IMS. This enables the label-free and multiplex determination
of locally resolved molecular signatures (e.g., proteins, peptides, lipids, and metabolites)
and allows their correlation with alterations in tissue histology [20,21]. Using large-scale
spatial MALDI data for machine learning has shown high potential for the development of
diagnostic histological tests [22,23]. In the current paper, we first classify FFPE-prepared
tumors of HGSOC patients as a discovery cohort into distinct molecular subtypes using
NanoString technology. Utilizing MALDI-IMS on the same FFPE tissue samples we estab-
lished a novel prognostic proteomic signature able to reliably stratify HGSOC patients by
molecular subtype.
2. Results
2.1. Two-Pronged Subtype Classification Workflow
In the present study, we followed a two-pronged approach to HGSOC subtype clas-
sification utilizing novel MALDI-IMS technology (Figure 1). First, ground truth labels
generated by NanoString analysis (predictive 39 gene signature) of RNA extracts from the
same tissue sections (patients, n = 279; cores, n = 382) were trained (random forest; RF)
on preprocessed MALDI-Imaging spectra and evaluated using the mean area under the
curve (AUC) metric. Since considerable differences in stroma content occur within the
sample cohort that could deteriorate classification performance, an alternative approach
that excludes spectra associated with stroma tissue was implemented. To that end, a
stroma-labeled dataset (patients, n = 19; cores, n = 35) was procured and a predictor for
stroma- associated spectra trained [24]. Using these models stroma spectra were excluded
from the subtype-labeled dataset and subtype classifiers were retrained and evaluated.
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Figure 1. Workflow for the stratification of high-grade serous ovarian cancer (HGSOC) patients.
Study workflow diagram of performed analysis (blue) including NanoString analysis (39 gene
signature) and MALDI-Imaging; computational analysis by random forest (RF; aquamarine) and
MALDI-Imaging datasets (yellow).
2.2. Subtype Identification via NanoString Analysis
FFPE tumor tissue sections from 279 HGSOC patients were analyzed using NanoS-
tring technology and a predictive 39 gene signature established ground truth subtype
labels to supervise machine learning. Of those tumors 105 (37.6%) were classified as mes-
enchymal, C1, and 77 (27.6%), 44 (15.8%), and 53 (19.0%) as subtypes immunoreactive
C2, differentiated C4, and proliferative C5, respectively. The GSE9891 reference subtype
distribution (n = 204) based on gene expression classification showed 40.2% (C1), 22.5%
(C2), 20.1% (C4), and 17.2% (C5) for the four subtypes within the AOCS dataset [7].
2.3. Distinct Survival Characteristics of Molecular Subtypes
Several studies have shown links between patient outcome and sub-classifications of
HGSOC [4–9]. With regard to the clinical parameters in our characterized HGSOC patients
(n = 279), survival curves of this cohort confirmed significant differences in estimated
progression-free survival (PFS) and overall survival (OS) survival (p < 0.021 and p < 0.0098)
associated with the distinct molecular subtypes (Figure 2). Patients harboring the C1
subtype were observed to have the worst prognosis for both PFS and OS rate while patients
exhibiting the C2 subtype displaying elevated survival. On the other hand, patients with
the C4 and C5 subtypes share similar survival characteristics.
Figure 2. Kaplan–Meier estimated survival rates of HGSOC patients stratified into molecular subtypes by NanoString
analysis. Non-parametric survival estimates of (A) progression free survival and (B) overall survival of HGSOC patients.
2.4. Accumulation of Proteomics Data by MALDI-IMS
Primary tumor tissue sections of HGSOC patients (n = 279) prepared as eight tissue
microarrays (TMAs) were consecutively measured by MALDI-IMS. Mass spectra were
extracted, and total ion count (TIC) normalized in the SCiLS Lab software (SCiLS GmbH,
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Bremen, Germany). Peak picking resulted in a total of 540 aligned m/z values in a mass
range between m/z 600 and 3200 (Table S1).
To implement a strategy to exclude stroma-associated spectra from the measurements,
an additional MALDI-IMS dataset of HGSOC patients (n = 19) with labeled stroma com-
partment was procured. Similarly, mass spectra were extracted and normalized. In total,
the full spectrum of the dataset consisting of 8.668 m/z values in a mass range between m/z
600 and 3200 was extracted (Table S1).
2.5. Classification of Stroma Compartments
Due to the limitations of MS sensitivity, decimal deviations in detected masses can
lead to distinct feature sets in datasets processed at different times or facilities. However,
for the purpose of applying a trained model to another dataset an identical feature set is
required. Therefore, feature parity was established by aligning and sub-setting the full
spectrum stroma-labeled data down to the 540-peak-picked features of the subtype-labeled
dataset. Subsequently, feature selection was performed, which identified a 135 peptide
signature able to discriminate stroma from malignant areas. Machine-learning methods
were trained on three randomized and stratified subsets of the stroma-labeled dataset.
The models classified spectra belonging to the stroma compartment with a mean AUC of
0.999 and false discovery rates below 1.0% (Table S2). One of the most predictive genes
for malignancy was identified as histone H1.2 (H1-2) (Figure 3, Table S1). Although the
majority of peptides displayed increased expression in malignant areas, some peptides
like 836,359 m/z which belongs to the stromal activation markers alpha-1 type I collagen
(COL1A1) were increased in stroma tissue.
Figure 3. Juxtaposition of stroma labeling and feature intensity of 1106.719 m/z (histone H1.2). A
subset of four stroma-labeled tumor cores depicted as (A) spatial distribution of expertly annotated
stroma and malignant areas, and (B) a spatial distribution of intensities measured at 1106.719 m/z
showing exclusive expression in malignant areas.
2.6. Discovery of Predictive Proteomic Signature of Tumor Subtypes
To determine discriminative m/z values and identify a proteomic signature, feature
selection via Gini importance ranking was performed resulting in 135 m/z values. In
combination, these features were able to distinguish patient populations based on their
HGSOC subtype (Figure 4).
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Figure 4. MALDI-Imaging-derived proteomics signature of 135 peptides from HGSOC subtype.
Subtypes are shown as follows: (A) C1, mesenchymal; (B) C2, immunoreactive; (C) C4, differentiated;
and (D) C5, proliferative. In total, feature selection resulted in 135 features in a mass range between
m/z 600 and 3200. Highlighted m/z values indicate features with high differential in average intensities
across subtypes.
A two-pronged machine learning approach was implemented utilizing RFs to classify
HGSOC subtypes from NanoString-supervised MALDI-IMS data. RF learners were applied
to three randomized and stratified subsets of the dataset. Simultaneously, we applied the
predictive proteomic signature to first exclude stroma, followed by the prediction of
subtypes (Figure 5B) as strong variations of intensities can be observed between malignant
and stromal compartments that are not specific to HGSOC subtypes and would interfere
with subtype prediction.
Figure 5. Visualization of spatial distribution of characteristic m/z values for representative tissue
cores of each HGSOC subtype. (A) H&E staining of four representative tissue cores. (B) Intensity
distribution of identified malignancy marker histone H1.2 (H1-2; 1106.719 Da) and highly subtype-
predictive actin, aortic smooth muscle (ACTA2; 976.490 Da). Red outlines indicate the malignant area
by reference to H1-2 intensity (not the signature).
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Subsequently, classifications were evaluated based on mean AUC. A mean AUC of
0.983 and 0.988 was observed for the complete subtype-labeled sets and those without
stroma, respectively (Figure 6; Table S2). The predictions had a mean balanced accuracy of
0.927 ± 0.012 (0.945 ± 0.008; without stroma) and a mean false discovery rate of 10.2% (8.0%).
Figure 6. AUC analysis of RF model on stroma-labeled datasets, subtype-labeled datasets with and
without spectra associated with the stroma compartment. Area under the curve (AUC) analysis
of (A) stroma classification, (B) subtype classification, and (C) consecutive stroma and subtype
classification such that spectra corresponding to stroma were excluded. (D) Average AUC for each
subtype following a one-vs.-one strategy for the dataset with (left) and without stroma (right).
Out of 135 discriminative peptides of the MALDI imaging signature, 91 peptides
could be identified as 56 proteins by matching with the nano-liquid chromatography (nLC)-
MS/MS data set (acquired from the adjacent tissue section) (see Table S1). In terms of
classification, the features associated with the proteins actin, aortic smooth muscle (ACTA2),
heat shock cognate 71 kDa protein (HSPA8), histone H2A variants (H2A), and 60 kDa heat
shock protein, mitochondrial (HSPD1) had the highest relevance.
3. Discussion
Ovarian cancer is distinguished histologically with even further genetic and pro-
gressive diversity within each histotype. HGSOC is the deadliest form of ovarian cancer
while at the same time being the most commonly diagnosed clinically. Distinct molecular
subtypes of HGSOC were previously described by gene expression analysis with clinical
relevance. However, these have not yet been established in clinical practice for the stratifi-
cation of patients for targeted therapeutic approaches, even though biological variation
in treatment response was shown [25]. It is therefore of high importance to establish
standardized, reproducible, and reliable molecular assessment protocols to stratify patients
for personalized treatment in order to improve their prognosis. Furthermore, patient
stratification could aid the investigation of drug efficacy and diverse patient response in
clinical trials as part of pharmaceutical research [26]. Here we present a proof-of-concept
study that demonstrates a novel approach for the highly specific and sensitive stratification
of patients for personalized treatment based on molecular subtypes of HGSOC utilizing
MALDI-IMS. Furthermore, we demonstrate the versatility of MALDI-IMS by also reliably
annotating stroma in tumor cores.
MALDI-IMS is a novel spatial mass spectrometric technique, combining molecular
analysis with conventional histologic assessment by H&E staining (Figure 5A) without
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the requirement for any labels (unsupervised) or prior knowledge of the target tissue, and
provides an unbiased visualization of the arrangement of biomolecules in tissue. Despite
the initial instrument cost, MALDI-IMS is a time and cost-effective technology capable
of high-throughput in situ determination of proteomics signatures at FFPE tumor tissue
specimens. Unlike other immune-based analytic methods that rely on individual biomark-
ers, which are limited by the efficacy of antibodies and the inability to investigate large
quantities of targets simultaneously, MALDI-IMS analyses the distribution of hundreds of
proteins (peptides) directly in a continuous measurement. Currently, there are no reliable
markers at hand for standard immunohistochemical classification of HGSOC subtypes.
The relatively simple and standardized workflow utilizing FFPE-prepared tissue samples
and automation make MALDI-IMS an optimal technique to stratify HGSOC patients. Since
this type of analysis is an unsupervised approach, beyond the determination of molecular
subtypes of HGSOC, MALDI-Imaging combined with machine learning is a promising
strategy to identify spatial proteomics signatures for various clinical discovery studies,
including patient prognosis, relapse risk, and response to treatment.
Our recently published data showed that MALDI-IMS can reliably detect the histolog-
ical subtypes of ovarian cancer and predict high-risk early-stage HGSOC patients [24,27].
In this presented follow-up study, a MALDI-Imaging-derived proteomic signature (135
peptides) was identified as being able to accurately classify molecular subtypes of HG-
SOC. To that end, tumor cores were prepared from FFPE tissue blocks and analyzed by
MALDI-IMS. Simultaneously, NanoString classification was performed on the same tissue
blocks from which the tumor cores originated. Following limited classification quality
testing of machine-learning algorithms, RF learners were trained supervised by NanoString
labels to classify HGSOC subtypes (Table S2). In a second step, an approach to exclude
stroma-associated spectra was implemented in order to reduce noise and improve the
model quality.
For this study, we have curated a representative cohort of 279 HGSOC patients that
both in subtype distribution and clinical outcome aligns with established knowledge.
NanoString classification of 279 HGSOC patient samples resulted in a subtype distribution
similarly observed in the AOCS patient cohort sequenced on Affymetrix U133 Plus 2 chips.
Furthermore, in agreement with previous findings including from the AOCS study, patients
that harbored tumors of the mesenchymal subtype C1 displayed trends for significantly
earlier relapse and shorter OS. In contrast, the immunoreactive subtype C2 correlated with
later relapse and longer OS [9]. This indicates that the underlying molecular background
that gives rise to HGSOC subtypes and clinical diversity is tangible both on the gene
expression and the proteomic level. In fact, the high classification performance of our
proteomic signature validates NanoString classification of HGSOC subtypes.
Moreover, we have implemented a novel strategy to accurately annotate the stroma
compartment of tissue cores based on MALDI-IMS data. This approach provided near-
perfect stroma classifications and could constitute a step towards automated annotation
of stroma within tissues cores or sections by predictive proteomic signatures. Such an
approach is versatile and could be used as described herein as a normalization strategy
similar to that described by Schwede et al. (2020) or to aid large-scale pathological assess-
ments of tissue samples, such as the computer-aided estimation of tumor–stroma ratio
(TSR) in colorectal cancer [16,28].
In this context, a specific peptide linked to histone H1.2 was observed to be highly
discriminative with nearly exclusive expression in malignant tissue. The apparent role
of linker histone H1.2 in directing the genome-wide association of the tumor suppressor
protein pRb with chromatin and, thus, exerting global influence on cell-cycle control by facil-
itating pRb binding near E2F target genes was previously described by Munro et al. (2017).
Furthermore, H1-2 was observed to be overexpressed in cancer cells acting as a silencer
of multiple growth suppressors dependent on EZH2-mediated H3K27me3 resulting in
modulation of the chromatin architecture [29].
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In general, we have observed multiple clinically relevant genes each linked to several
peptides that exhibit similar expression patterns when grouped by subtype (Figure S1).
Those genes typically showed increased expression in the C2 and C4 subtypes, and thus
were correlated with better patient outcome. This was confirmed by survival data of
HGSOC patients of stage 2 and 3 provided by the Kaplan–Meier Plotter for ovarian cancers
(https://kmplot.com/, accecssed on 15 December 2020). However, for this microarray-
based analysis most genes are represented by multiple probes with only some in support of
this hypothesis. Furthermore, direct correlations between transcript and protein levels are
not always possible, such that mRNA expression does not necessarily translate to MALDI-
Imaging-derived proteomics. It is therefore not surprising to observe little overlap between
prognostic gene signatures and our proteomic signature. A complementary strategy might
benefit the identification of novel biomarkers.
Preliminary analysis revealed correlations between sets of features suggesting that a
reduction of features could potentially provide better classification performance (Figure S2).
Alternative thresholding methods based around the biggest gaps in the ordered feature-
importance scores will result in few highly informative features needing to be re-evaluated
independently in the future. However, it is unlikely that these features would lead to
individual biomarkers that would exhibit sufficient diagnostic efficacy to stratify patients.
MALDI-Imaging-derived signatures comprising fewer features complicate the assignment
of uniquely identifiable proteins as each mass could in isolation belong to several proteins.
Furthermore, despite specific peptides being highly predictive, they might only provide
meaningful classifications in the context of a signature.
Recent studies have demonstrated a link between HGSOC subtypes and drug re-
sponse [30,31]. Kommoss et al. (2017) described the efficacy of bevacizumab, an anti-
angiogenic monoclonal antibody for the vascular endothelial growth factor (VEGF) recep-
tor ligand VEGF-A, as being especially beneficial for treatment of the proliferative (C5)
and mesenchymal (C1) subtypes. Hence, subtypes displaying the poorest survival derive
greatest benefit from such therapy. This suggests that treatment with an already FDA-
approved and utilized therapeutic might benefit from patient stratification. Furthermore,
the ongoing research characterizing HGSOC subtypes elucidates potential therapeutic
targets exploiting subtype-specific molecular mechanisms with many novel approaches
to targeted treatment of HGSOC currently being proposed [11,12,31,32]. Hence, patient
stratification might benefit clinical management in the near future. The advance of MALDI-
IMS into clinical practice as described by Aichler et al. (2015) and the increasing relevance
of HGSOC subtypes in the context of novel therapeutics make patient stratification by
MALDI Imaging a promising technology [33].
4. Materials and Methods
4.1. HGSOC Patient Cohort
All tissue samples were collected during surgery at Charité, Department for Gynecol-
ogy after patients gave their informed consent. This study including sample collection and
use for research was approved by the local ethics committee of the Charité Medical Univer-
sity Berlin (AVD-No. 2004-000034) and conducted in accordance with the declaration of
Helsinki. High-grade serous histotyping of epithelial ovarian cancer (EOC) was performed
by an experienced gynecological pathologist at Charité, Institute of Pathology. OS and
PFS data were available (median OS = 33.9 months, n = 238; median PFS = 17.4 months,
n = 240) with a median follow-up (FU) of 62 months (Table S3).
4.2. RNA Extraction and Classification by NanoString Technology
Total RNA extraction was performed on FFPE tissue sections using the Maxwell
RSC instrument by Promega (Promega GmbH, Walldorf, Germany) following the man-
ufacturer’s instructions. Two 5 µm thick sections were cut from each paraffin block and
subsequently transferred to a 1.5-mL tube. Tissue core extraction was supervised by an
experienced reference pathologist to maximize tumor content and exclude fibrotic and
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necrotic areas. H&E staining of all tumor samples in this study confirmed at least 30%
tumor content (median tumor content 60%). To establish learnable ground truth subtype
labels for each tumor core, molecular subtypes were identified by NanoString classification
as described by Leong et al. [18,19]. To this end, expression data of 279 patients’ tumor
samples were pre-processed and normalized with the NanoStringNorm R library version
1.2.1, in compliance with the NanoString data analysis guidelines (PDF file “nCounter
Gene Expression Data Analysis Guide” at https://www.nanostring.com/support/product-
support/support-workflow, accessed on 14 August 2020).
More specifically, background correction was performed as ’Background Thresholding’
with a threshold of ’mean + 2 standard deviations above the mean’. Positive control
normalization was applied using the geometric mean to compute normalization factors.
Finally, CodeSet Content Normalization was applied using the geometric mean of four
housekeeping genes (ACTB, GAPDH, GUSB, and TBP). Subsequent analyses including
subtype classification utilizing a classifier signature (39 genes) were conducted using the
normalized, log-scaled expression data [18].
4.3. Statistical Analysis of Patient Outcome
Non-parametric Kaplan–Meier analysis for progression free, calculated from the time
of diagnosis to disease recurrence, and overall survival was performed for 279 patients
stratified by NanoString analysis to assess the clinical relevance of molecular subtypes of
HGSOC. Statistical tests were performed with survival and survminer R packages.
4.4. Reference Dataset for Subtype Classification Based on Gene Expression Analysis
HGSOC samples (n = 204) from the GSE9891 dataset were downloaded from the Gene
Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/, accessed on 16 July 2019)
repository with distinct subtype classification available.
4.5. MALDI-Imaging and Peptide Identification by “Bottom-Up”-nHPLC Mass Spectrometry
Formalin-fixed paraffin-embedded HGSOC TMAs were randomly assembled and
prepared at the Institute of Pathology, Charité Medical University Berlin. For MALDI
imaging analysis, 6-µm sections from the TMA were transferred onto indium–tin-oxide
slides (Bruker Daltonik, Bremen, Germany), dewaxed and subsequent antigen retrieval
was performed as previously described [24,27]. MALDI-Imaging analyses were executed
in reflector mode, detection range of m/z 800–3200, 500 laser shots per spot, sampling rate
of 1.25 GS/s and raster width of 50 µm on Rapiflex MALDI-TOF/using flexControl 3.0
and flexImaging 3.0 (Bruker Daltonik, Bremen, Germany). SCiLS Lab software (Version
2021a Pro, SCiLS GmbH, Bremen, Germany) was used to convert MALDI-Imaging data
to the SCiLS Lab file format. In order to improve the comparability between the sample
sets simultaneous pre-processing of the data sets was conducted with following param-
eters: convolution baseline removal (width: 20) and TIC normalization. For subsequent
processing, the data were exported to R (Version 3.6.0).
In order to identify m/z values, complementary nLC-MS/MS on adjacent tissue sec-
tions were carried out as published previously [24,34]. Identified peptides with the lowest
mass difference to peptides of the nLC-MS/MS reference list were assumed to be a match
(<1.0 Da) in accordance with Cillero-Pastor et al. (2014) guidelines [35].
4.6. Dataset Preparation
By its nature, machine learning is sensitive to the quantity and quality of the input
data [36]. Preprocessing methods including normalization and filtering can be applied to
improve classification quality. Following these standards, machine learning datasets were
generated by initially scaling all spectra via the functions included in the dataPreparation
R package. Subsequently, the datasets were generated as follows: (i) identification of the
most infrequent subtype in the complete dataset and inclusion of all corresponding spectra;
(ii) iterative sampling of tumor cores and inclusion of their spectra until each subtype was
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represented by approximately equal numbers of spectra; (iii) repeating step (i) and (ii) three
times in total; (iv) for each randomly created stratified subset performing a stratified partition
(70% training and 30% testing; Table S4). Finally, feature selection was performed on the
training set using Gini importance, the inherent ranking of features within the decision trees
of a RF [37]. Top-ranked features were selected with a 25% cut-off (Figure S2).
4.7. Exclusion of Spectra of Stromal Origin
A stroma-annotated MALDI dataset of HGSOC patients (n = 19, 35 cores) was procured
as described [24]. However, the application of a trained model is limited to data with an
identical feature set. Thus, feature parity had to be established first. Features of the
stroma-labeled data were aligned and subsequently subsetted to the feature set of the
subtype-labeled data with a maximum difference of <0.25 Da. The data was processed
following steps (i)–(iv) of the Section 4.6 generating three scaled, stratified, and feature-
selected datasets.
Individual RF classifiers were trained and applied to predict stroma spectra in the
scaled but otherwise complete subtype-labeled dataset. Using a consensus approach a
particular spectrum was excluded if all three models independently classified it to be of
stromal origin. Finally, steps (i)–(iv) of the Section 4.6 were repeated on this new dataset.
4.8. Machine Learning and Model Analysis
The machine learning interface was constructed using the mlr3 building blocks in
R [38] with the additional ranger R package [39] implementing RF classifiers used to predict
sub-classifications of HGSOC. Grid search parameter optimization was performed using a
resolution of 4- and 3-fold cross-validation. Optimized parameters were applied to three
learners and subsequently trained and tested on one of the three randomized datasets
each. Predictions were evaluated by mean AUC analysis and a vast set of quality metrics
implemented in the mltest R package. AUC analysis was performed with the multiROC
and pROC (binary classification) R packages [40].
5. Conclusions
MALDI-IMS is applied in an increasing number of biological studies, although adop-
tion into diagnostic routine for clinical management has not yet occurred extensively.
MALDI-Imaging presents a promising technology that when combined with expansive
machine learning can be used to screen for prognostic signatures for risk assessment as well
as to define biomarkers of treatment response. Eventually, such signatures might be utilized
to support the clinical management that requires highly specific and sensitive stratification,
in combination with detailed histopathological information. Here, we demonstrate a novel
strategy utilizing MALDI-IMS for the classification of HGSOC subtypes to identify patients
that might benefit from innovative therapeutic treatments.
Supplementary Materials: The following are available online at https://www.mdpi.com/2072-669
4/13/7/1512/s1, Figure S1: Intensities of the peptides assignable to HIST1H2BC in conjunction with
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peptide signature; Table S1: List of proteins assigned to masses included in the 135 peptide signature
and full spectra; Table S2: Comprehensive model evaluation of machine learners and parameters;
Table S3: Patient cohort summary; Table S4: Characterization of machine learning input datasets.
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